Johnson & Johnson Lifts 2026 Sales Guidance as Innovative Medicine Leads

Executive Summary

• Johnson & Johnson reported third-quarter 2026 operational sales growth of 6%, ahead of analyst consensus, with quarterly sales of more than $25 billion, according to the company's prepared earnings remarks.
• Innovative Medicine delivered operational sales growth of 7.9%, while MedTech grew 2.5% and fell short of company expectations for the segment, the remarks state.
• Johnson & Johnson raised and tightened its full-year 2026 operational sales guidance to a range of 6.7% to 7.1%, representing $100.7 billion at the midpoint, the company said.
• The company completed the $1 billion acquisition of Firefly Bio and entered a collaboration with Sail Biomedicines during the quarter, and expects a combined dilutive impact of $1.36 per share on full-year adjusted earnings per share in 2027, according to the remarks.

Key Takeaways

• Johnson & Johnson's quarter was carried by Innovative Medicine, where oncology grew approximately 17% and immunology brand TREMFYA grew 68%.
• MedTech underperformed internal expectations, with management naming Cardiovascular and Surgery outside the U.S. as the areas that need improvement.
• Guidance was raised on the strength of year-to-date performance, even as the company absorbs $0.64 in earnings-per-share dilution from the Firefly Bio and Sail Biomedicines transactions.
• The planned separation of DePuy Synthes remains on track for mid-2027, with management leaning toward a spin.

Johnson & Johnson Raises 2026 Guidance as Innovative Medicine Carries the Quarter

Johnson & Johnson ended the third quarter with more than $25 billion in sales, 6% operational growth, and sequential improvement over the second quarter. Chief Executive Officer Joaquin Duato framed the result as confirmation of 2026 as a year of accelerated growth, and the company is now positioned to exceed $100 billion in annual revenue for the first time in its 140-year history. The raised guidance midpoint of $100.7 billion in operational sales, or 6.9% growth, is the clearest signal of that confidence.

The composition of the growth matters more than the headline number. Innovative Medicine grew 7.9% operationally with eight brands in double digits, while MedTech grew 2.5% and missed internal expectations. Chief Financial Officer Joe Wolk told investors the company is clear on where MedTech needs to improve, specifically Cardiovascular and Surgery outside the U.S., and that corrective action is underway. The gap between the two segments is now the central operational question for the company heading into 2027.

Johnson & Johnson's Oncology Franchise Approaches a $50 Billion Ambition

Oncology grew approximately 17% in the quarter, and Duato described the multiple myeloma portfolio and pipeline as unmatched, with 80% of patients receiving a Johnson & Johnson therapy as part of their treatment journey. The company said new Phase 3 results announced in July showed the TECVAYLI plus TALVEY combination reduced the risk of disease progression or death by 89% as early as the second line of treatment. RYBREVANT sales rose 64%, and the company expects U.S. approval of RYBREVANT FASPRO in advanced head and neck cancer by the end of the year.

In bladder cancer, INLEXZO reached roughly $200 million in year-to-date sales and nearly one in three eligible patients started on an INLEXZO regimen in the quarter, one year after launch. Management's stated ambition is to become the top oncology company by 2030, with sales projected to exceed $50 billion. That projection is a company forecast, not a measured result, and depends on pipeline readouts the company expects in the fourth quarter, including pasritamig and JNJ-6143 data.

Johnson & Johnson's Immunology Momentum Runs Through TREMFYA and ICOTYDE

TREMFYA delivered 68% sales growth, and the company said it is now the top IL-23 inhibitor in new-to-brand share in Crohn's disease, ulcerative colitis, and psoriatic arthritis in the U.S. Johnson & Johnson cited the STAR study in describing TREMFYA as the first and only IL-23 inhibitor to demonstrate positive outcomes in axial disease clinical trials, and management believes the drug can grow into a $10 billion-plus franchise. That is a stated expectation, not a confirmed milestone.

ICOTYDE, the company's targeted oral peptide for plaque psoriasis, has been used by more than 20,000 patients through nearly 9,000 prescribers since its U.S. launch, with broad coverage across national plans. IMAAVY was approved as the first advanced treatment specifically for warm autoimmune hemolytic anemia, extending its reach beyond generalized myasthenia gravis. The company also announced a July collaboration with Sail Biomedicines on in vivo CAR-T approaches for immune-mediated diseases.

Related: Advanced Materials Move From Lab Breakthroughs to Factory Economics

Johnson & Johnson's MedTech Portfolio Shows Uneven Progress

Cardiovascular produced one of the segment's stronger results, with SHOCKWAVE growing 17% and VARIPULSE surpassing 100,000 AFib patients treated worldwide. A retrospective analysis cited by the company showed VARIPULSE with a 68% lower risk of adverse cardiac events compared to a competing pulsed field ablation platform. VARIPULSE Pro, which the company says delivers five-times faster ablation, is driving double-digit growth in Europe and received approval in Japan last week, with U.S. approval of VARIPULSE Pro expected in the fourth quarter.

Heart Recovery remained the weak point. Physician selectivity continued to affect ABIOMED performance, and management said corrective action is being taken while it continues to invest in clinical evidence. Results from the HRPCI Protect IV trial, which will enroll 1,252 patients, are expected in 2027. In Surgery, Johnson & Johnson received FDA De Novo authorization in July for OTTAVA, described as the first table-integrated soft tissue robotic system, and has signed its first commercial customer. Revenue contribution is expected to build over time, with the goal of establishing OTTAVA as a significant pillar of the Surgery portfolio by the end of the decade.

Johnson & Johnson Balance Sheet, Litigation, and the DePuy Synthes Separation

Johnson & Johnson ended the third quarter with approximately $17 billion in cash and marketable securities and approximately $45 billion in debt, a net debt position of roughly $28 billion, generating more than $6 billion in free cash flow in the quarter. Full-year free cash flow guidance stands at approximately $21 billion. The July agreement to resolve ovarian talc litigation for $5.5 billion is reflected in third-quarter GAAP results and is conditioned on the express participation of at least 95% of remaining ovarian claims; the company said it is trending to meet that threshold.

For deeper context, see our AI analysis: "Pinterest Debuts Ask Pinterest AI Shopping App in 2026".

On the planned separation of DePuy Synthes, Wolk said the company remains on track for mid-2027 and is leaning toward a spin as the best option to create long-term shareholder value. The company expects to provide more detail on its 2027 outlook at its Enterprise Business Review on December 8.

What This Means for Practitioners

For investors and procurement teams tracking Johnson & Johnson, the quarter sharpens the case for segment-level rather than consolidated reading. Innovative Medicine is doing the work, with oncology and immunology brands carrying growth and pipeline catalysts clustering in the fourth quarter. MedTech is the drag, and management has named Cardiovascular and Surgery outside the U.S. as the specific problem areas. The raised guidance midpoint of $100.7 billion in operational sales embedding $0.64 of dilution from the Firefly Bio and Sail Biomedicines deals means base-business performance is running ahead of the reported figure. Watch the December 8 Enterprise Business Review for 2027 detail.

Johnson & Johnson Implementation Risks

The main risks visible in the source are execution-dependent. MedTech improvement depends on corrective action in Cardiovascular and Surgery outside the U.S., and management has not quantified the expected recovery. Several oncology and immunology catalysts cited for the fourth quarter, including pasritamig and JNJ-6143 data and U.S. approval of RYBREVANT FASPRO, are pending and not assured. The ovarian talc resolution remains conditioned on reaching 95% participation from remaining claimants. ABIOMED performance remains affected by physician selectivity, and OTTAVA revenue contribution is expected to build only over time. Johnson & Johnson's own forward-looking statement cautions that actual results could vary materially.

Additional coverage: Mazama Energy Raises $135 Million to Scale Superhot Geothermal

Disclosure: This article was produced independently by Business 2.0 News and is based solely on Johnson & Johnson's published prepared remarks. Business 2.0 News is editorially independent of the companies covered.

Source note: all facts in this article derive from Johnson & Johnson's Q3 2026 CEO and CFO prepared remarks.